AJANTPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.1
| Stock Code | AJANTPHARM | Market Cap | 35,460 Cr. | Current Price | 2,837 ₹ | High / Low | 3,021 ₹ |
| Stock P/E | 37.6 | Book Value | 330 ₹ | Dividend Yield | 0.98 % | ROCE | 33.0 % |
| ROE | 25.7 % | Face Value | 2.00 ₹ | DMA 50 | 2,705 ₹ | DMA 200 | 2,635 ₹ |
| Chg in FII Hold | -0.56 % | Chg in DII Hold | 0.68 % | PAT Qtr | 245 Cr. | PAT Prev Qtr | 250 Cr. |
| RSI | 58.2 | MACD | 27.1 | Volume | 1,35,278 | Avg Vol 1Wk | 1,10,218 |
| Low price | 2,022 ₹ | High price | 3,021 ₹ | PEG Ratio | 4.74 | Debt to equity | 0.01 |
| 52w Index | 81.6 % | Qtr Profit Var | -2.94 % | EPS | 75.5 ₹ | Industry PE | 29.1 |
📊 Analysis: AJANTPHARM is trading at ₹2,837, above both its 50 DMA (₹2,705) and 200 DMA (₹2,635), indicating strong bullish momentum. RSI at 58.2 suggests moderate strength without being overbought, while MACD (27.1) shows a positive crossover, supporting upward momentum. Intraday volume (1,35,278) is higher than the average weekly volume (1,10,218), reflecting active participation. Fundamentals are robust with high ROCE (33.0%), ROE (25.7%), and minimal debt-to-equity (0.01). Valuation is slightly stretched (P/E 37.6 vs industry 29.1, PEG 4.74), but momentum favors intraday trading opportunities.
💡 Optimal Buy Price: ₹2,820–2,830 if price consolidates near support.
🎯 Profit-Taking Levels: ₹2,880–2,900 (short-term resistance zone).
🛡️ Stop-Loss: ₹2,800 to protect against downside risk.
⏱️ Exit Strategy (if already holding): Exit if price fails to sustain above ₹2,880 with strong volume. Momentum indicators suggest upside potential, but profit booking should be considered near resistance levels to avoid reversal risk.
Positive
- Strong ROCE (33.0%) and ROE (25.7%) highlight efficient capital use.
- Trading above both 50 DMA and 200 DMA indicates bullish trend.
- EPS of ₹75.5 reflects strong earnings power.
- Debt-to-equity ratio of 0.01 shows virtually debt-free balance sheet.
- 52-week index return of 81.6% demonstrates strong investor confidence.
Limitation
- P/E ratio of 37.6 is higher than industry average (29.1).
- PEG ratio of 4.74 suggests overvaluation relative to growth.
- Quarterly PAT declined slightly from ₹250 Cr. to ₹245 Cr. (-2.94%).
- FII holding decreased by 0.56%, showing reduced foreign interest.
Company Negative News
- No major negative news reported, but slight earnings decline raises caution.
Company Positive News
- Strong fundamentals with high ROCE and ROE.
- DII holding increased by 0.68%, showing domestic institutional support.
Industry
- Industry P/E at 29.1 indicates sector is moderately valued.
- Pharmaceutical sector benefiting from strong demand and global healthcare expansion.
Conclusion
⚖️ AJANTPHARM shows strong fundamentals and bullish technical indicators, making it a good candidate for intraday trading. Entry near ₹2,820–2,830 with profit-taking around ₹2,880–2,900 is optimal. Traders should monitor volume and momentum closely to maximize gains while protecting against reversal risks.